Benitec Biopharma Inc. (BNTC) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 23.39M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 26.41M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -51.19M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $23.39M | (m) | $26.41M | $-51.19M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $18.37M | (m) | $26.26M | $-46.60M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $18.57M | (m) | $26.41M | $-48.35M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $18.12M | (m) | $22.17M | $-45.78M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $18.33M | (m) | $17.43M | $-41.77M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $18.15M | (m) | $4.43M | $-30.14M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $14.73M | (m) | $2.02M | $-24.09M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $14.77M | (m) | $1.17M | $-22.41M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $15.61M | (m) | $830.00K | $-22.49M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $15.28M | (m) | $503.00K | $-21.49M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $15.88M | (m) | $382.00K | $-21.69M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $14.54M | (m) | $241.00K | $-20.38M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $12.77M | (m) | $452.00K | $-19.08M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $12.76M | (m) | $493.00K | $-19.27M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $11.77M | (m) | $614.00K | $-18.39M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $11.15M | (m) | $901.00K | $-17.61M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $11.27M | (m) | $870.00K | $-17.85M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $10.42M | $75.00K | $981.00K | $-16.97M | (m) | 13888.00% | 1308.00% | (m) | (m) |
| 2021-12-31 | $11.00M | $28.00K | $1.02M | $-17.30M | (m) | 39300.00% | 3657.14% | (m) | (m) |
| 2021-09-30 | $9.03M | $4.00K | $867.00K | $-15.73M | (m) | 225650.00% | 21675.00% | (m) | (m) |
| 2021-06-30 | $7.02M | $59.00K | $634.00K | $-13.60M | (m) | 11898.31% | 1074.58% | (m) | (m) |
| 2021-03-31 | $5.61M | $22.00K | $412.00K | $-12.63M | (m) | 25481.82% | 1872.73% | (m) | (m) |
| 2020-12-31 | $3.92M | $48.00K | $265.00K | $-10.95M | (m) | 8168.75% | 552.08% | (m) | (m) |
| 2020-09-30 | $3.35M | $124.00K | $220.00K | $-9.80M | (m) | 2703.23% | 177.42% | (m) | (m) |
| 2020-06-30 | $3.00M | $102.00K | $237.00K | $-8.28M | (m) | 2942.16% | 232.35% | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $4.57M | $12.20M | $672.00K | $2.58M | (m) | 37.44% | 5.51% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |